Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

75 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Quadrivalent meningococcal tetanus toxoid-conjugate booster vaccination in adolescents and adults: phase III randomized study.
Zambrano B, Peterson J, Deseda C, Julien K, Spiegel CA, Seyler C, Simon M, Hoki R, Anderson M, Brabec B, Áñez G, Shi J, Pan J, Hagenbach A, Von Barbier D, Varghese K, Jordanov E, Dhingra MS. Zambrano B, et al. Pediatr Res. 2023 Sep;94(3):1035-1043. doi: 10.1038/s41390-023-02478-5. Epub 2023 Mar 10. Pediatr Res. 2023. PMID: 36899125 Free PMC article. Clinical Trial.
A Randomized Controlled Study of a Fully Liquid DTaP-IPV-HB-PRP-T Hexavalent Vaccine for Primary and Booster Vaccinations of Healthy Infants and Toddlers in Latin America.
López P, Arguedas Mohs A, Abdelnour Vásquez A, Consuelo-Miranda M, Feroldi E, Noriega F, Jordanov E, B Chir S, Zambrano B. López P, et al. Among authors: b chir s, zambrano b. Pediatr Infect Dis J. 2017 Nov;36(11):e272-e282. doi: 10.1097/INF.0000000000001682. Pediatr Infect Dis J. 2017. PMID: 28719500 Clinical Trial.
Immune Response Persistence and Safety of a Booster Dose of the Tetravalent Dengue Vaccine in Adolescents and Adults Who Previously Completed the 3-dose Schedule 4-5 Years Earlier in Latin America: A Randomized Placebo-controlled Trial.
Coronel D, García-Rivera EJ, Rivera DM, Arredondo-García JL, Dietze R, Perroud AP, Cortés M, Bonaparte M, Wang H, Pagnon A, Jantet-Blaudez F, Peñalosa LAR, Dayan G, Zambrano B, DiazGranados CA, Noriega F. Coronel D, et al. Among authors: zambrano b. Pediatr Infect Dis J. 2020 Oct;39(10):961-968. doi: 10.1097/INF.0000000000002830. Pediatr Infect Dis J. 2020. PMID: 32932330 Clinical Trial.
Immunogenicity and Safety of a Quadrivalent Meningococcal Tetanus Toxoid-Conjugate Vaccine (MenACYW-TT) in Meningococcal Vaccine-Naïve Participants across a Broad Age Range (2-55 Years) in Japan: a Phase III Randomized Study.
Matsuoka O, Ujiie M, Kikuchi H, Otake S, Chansinghakul D, Inoue T, Varghese K, Sirisuphmitr N, Hashiguchi T, Zambrano B, Nakama T, Frago C, Jordanov E, Dhingra MS. Matsuoka O, et al. Among authors: zambrano b. Jpn J Infect Dis. 2023 May 24;76(3):174-182. doi: 10.7883/yoken.JJID.2022.272. Epub 2023 Jan 31. Jpn J Infect Dis. 2023. PMID: 36724939 Free article. Clinical Trial.
Correction: Quadrivalent meningococcal tetanus toxoid-conjugate booster vaccination in adolescents and adults: phase III randomized study.
Zambrano B, Peterson J, Deseda C, Julien K, Spiegel CA, Seyler C, Simon M, Hoki R, Anderson M, Brabec B, Áñez G, Shi J, Pan J, Hagenbach A, Von Barbier D, Varghese K, Jordanov E, Dhingra MS. Zambrano B, et al. Pediatr Res. 2024 Mar;95(4):1159. doi: 10.1038/s41390-023-02835-4. Pediatr Res. 2024. PMID: 37853068 Free PMC article. No abstract available.
75 results